On August 30, Fumihiko Urano, MD, PhD and colleagues had their research titled “Blocking CHOP-dependent TXNIP shuttling to mitochondria attenuates albuminuria and mitigates kidney injury in nephrotic syndrome,” published in “Proceedings of the National Academy of Sciences of the United States of America.”
Albuminuria is a symptom of glomerular disease and a leading cause of glomerulosclerosis, interstitial fibrosis and kidney function decline. “The molecular mechanism underlying albuminuria-induced kidney injury remains poorly defined.”
In this study, Urano and collaborators have identified CHOP (C/EBP homologous protein) and TXNIP (thioredoxin-interacting protein) as the molecular linkers between albuminuria-induced ER dysfunction and mitochondria dyshomeostasis.
By utilizing these linkers in their research, they find that targeting TXNIP offers a promising therapeutic strategy for treating nephrotic syndrome.